Clinical Trials
3 trialsNCT07322783 2026-01-07
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
Qingdao Central Hospital
Phase 2 Recruiting
NCT03126799 2022-04-06
AvaTa
National Cancer Center, Korea
Phase 2 Unknown
NCT03382795 2021-07-15
Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients
Korea University Guro Hospital
Phase 2 Unknown